Mouse Monoclonal GFPT1 Antibody

The GFPT1 antibody is a crucial tool for studying the enzyme glutamine-fructose-6-phosphate transaminase 1 (GFPT1), a key regulator of the hexosamine biosynthesis pathway (HBP). GFPT1 catalyzes the rate-limiting step converting fructose-6-phosphate to glucosamine-6-phosphate, initiating protein glycosylation processes essential for cellular signaling, stress responses, and post-translational modifications. Dysregulation of GFPT1 is linked to metabolic disorders, particularly diabetic complications, due to its role in glucose metabolism and insulin resistance. It is also associated with congenital myasthenic syndromes (CMS), where mutations impair neuromuscular junction function. Researchers use GFPT1 antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to quantify protein expression, assess tissue-specific localization, and explore its involvement in diseases. Commercial GFPT1 antibodies are typically validated for specificity against human, mouse, or rat samples, with both monoclonal and polyclonal variants available. Recent studies focus on GFPT1's interaction with cellular stress pathways, its impact on O-GlcNAcylation, and potential therapeutic targeting in metabolic or neuromuscular diseases. Proper controls, such as knockout cell lines, are recommended to confirm antibody specificity in experimental setups.